AVRA
  • Home
  • About
    • Who we are
    • What we do
    • The rationale for AVRA
    • A robust vaccine pipeline
    • The global and national context
    • Expected benefits
    • Governance and management
  • Key Activities
    • Antigen surveillance
    • Vaccine platform technologies
    • Adjuvant development
    • Antigen discovery
    • Animal models
    • Vaccine immunity
    • Vaccine manufacturing partners
    • Clinical trials
    • Education and training
  • People
  • Partners
  • News and Events
  • Contact
Menu
First antigen test pilot in low prevalence COVID-19 settings signals challenges for rollout

First antigen test pilot in low prevalence COVID-19 settings signals challenges for rollout

Mar 2, 2021

SARS-CoV-2 antibody signature

SARS-CoV-2 antibody signature

Mar 1, 2021

Mapping an effective immune response to COVID-19

Mapping an effective immune response to COVID-19

Feb 11, 2021

COVID variants and what they mean for the pandemic

COVID variants and what they mean for the pandemic

Feb 10, 2021

New method to assist fast-tracking of vaccines for pre-clinical tests

New method to assist fast-tracking of vaccines for pre-clinical tests

Jan 19, 2021

New defence against dengue and emerging mosquito-borne viruses

New defence against dengue and emerging mosquito-borne viruses

Jan 8, 2021

« Older Entries

ENQUIRIES

P 07 3346 1623  |  M 0499 880 791

The University of Queensland Logo The University of Sydney Logo The University of Melbourne Logo

© 2020 Australian Vaccine Response Alliance (AVRA)